Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.32 |
| ▸ | PLK1 | P53350 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948493 | 0.79 | SLC6A5 (0.46) | CA2CA1 | |
| Acetic Acid SCHEMBL25299883 | 0.77 | — | — | |
| Oxalic Acid SCHEMBL23926047 | 0.76 | SLC6A5 (0.43) | — | |
| Oxalic Acid SCHEMBL23926045 | 0.76 | SLC6A5 (0.43) | — | |
| SCHEMBL14197469 | 0.76 | CA2 (0.44) | HDAC3HDAC1CA2CA12CA1 | |
| SCHEMBL14575431 | 0.76 | CA2 (0.44) | HDAC3HDAC1CA2CA12CA1 | |
| SCHEMBL19594069 | 0.76 | CA2 (0.44) | HDAC3HDAC1CA2CA12CA1 | |
| SCHEMBL23948875 | 0.76 | — | — | |
| SCHEMBL20904578 | 0.76 | CA2 (0.44) | HDAC3HDAC1CA2CA12CA1 | |
| SCHEMBL26430827 | 0.76 | CA2 (0.44) | HDAC3HDAC1CA2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2021211984-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | HDAC3 3081/4885HDAC1 3306/4885CA2 2515/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | HDAC3 3081/4885HDAC1 3306/4885CA2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.